Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
61.66 USD | -0.08% | -4.88% | +11.82% |
May. 21 | Ani Pharmaceuticals Insider Sold Shares Worth $794,568, According to a Recent SEC Filing | MT |
May. 20 | ANI Pharmaceuticals Launches Kionex Suspension | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 39.36 times its estimated earnings per share for the ongoing year.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.82% | 1.2B | C- | ||
+37.74% | 723B | C+ | ||
+34.61% | 595B | B | ||
-2.07% | 369B | C+ | ||
+20.25% | 332B | B- | ||
+2.99% | 282B | C+ | ||
+17.19% | 244B | B+ | ||
+10.03% | 208B | B- | ||
-4.13% | 205B | A+ | ||
+7.43% | 166B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ANIP Stock
- Ratings ANI Pharmaceuticals, Inc.